| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Que Liu, Christen Anderson, Anatoly Broyde, Clara Polizzi, Rayne Fernandez, Alain Baron, David G Parke. Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovascular diabetology. vol 9. 2011-02-03. PMID:21080957. |
we hypothesized that chronic treatment with glp-1 or the exenatide analog ac3174 would improve cardiac function, cardiac remodeling, insulin sensitivity, and exercise capacity (ec) in rats with mi-induced chronic heart failure (chf) caused by coronary artery ligation. |
2011-02-03 |
2023-08-12 |
rat |
| Davida F Kruger, Bruce Bode, Geralyn R Spollet. Understanding GLP-1 analogs and enhancing patients success. The Diabetes educator. vol 36 Suppl 3. 2011-02-02. PMID:20736387. |
the incretin hormones, glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip), are now known to play major roles in endogenous glucose control, including regulation of insulin, glucagon, and hepatic glucose metabolism. |
2011-02-02 |
2023-08-12 |
Not clear |
| Jinpei Zhou, Shuaijian Ni, Huibin Zhang, Hai Qian, Yushi Chi, Wenlong Huang, Lu Yu, Xiaowen Hu, Wei Che. Synthesis and bioactivity evaluation of dipeptidyl peptidase IV resistant glucagon-like peptide-1 analogues. Protein and peptide letters. vol 17. issue 10. 2011-01-21. PMID:20594158. |
glucagon-like peptide -1 (glp-1) is an incretin hormone displaying glucose-dependent stimulation of insulin secretion and trophic effects on the pancreatic β-cells. |
2011-01-21 |
2023-08-12 |
mouse |
| T Vilsbøl. The effects of glucagon-like peptide-1 on the beta cell. Diabetes, obesity & metabolism. vol 11 Suppl 3. 2011-01-19. PMID:19878257. |
glucagon-like peptide-1 (glp-1) is an incretin hormone that is known to stimulate glucose-dependent insulin secretion. |
2011-01-19 |
2023-08-12 |
Not clear |
| A Sjöhol. Impact of glucagon-like peptide-1 on endothelial function. Diabetes, obesity & metabolism. vol 11 Suppl 3. 2011-01-19. PMID:19878258. |
the incretin hormones, such as glucagon-like peptide-1 (glp-1), induce the glucose-dependent secretion of insulin, improve beta-cell function and induce slowing of gastric emptying and feelings of satiety - which result in reduced food intake and weight loss. |
2011-01-19 |
2023-08-12 |
Not clear |
| M J Davies, R Donnelly, A H Barnett, S Jones, C Nicolay, A Kilcoyn. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes, obesity & metabolism. vol 11. issue 12. 2011-01-19. PMID:19930005. |
the helping evaluate exenatide in overweight patients with diabetes compared with long-acting insulin (heela) study was designed to examine whether the glucagon-like peptide-1 (glp-1) receptor agonist, exenatide, could improve hba1c (< or =7.4%) with minimal weight gain (< or =1 kg) compared with insulin glargine. |
2011-01-19 |
2023-08-12 |
Not clear |
| Leigh Perreault, Chiara Dalla Man, Devon M Hunerdosse, Claudio Cobelli, Bryan C Bergma. Incretin action maintains insulin secretion, but not hepatic insulin action, in people with impaired fasting glucose. Diabetes research and clinical practice. vol 90. issue 1. 2011-01-18. PMID:20708814. |
to determine whether altered glp-1 activity contributes to the abnormal endogenous glucose production (egp) and insulin secretion characteristic of people with impaired fasting glucose (ifg). |
2011-01-18 |
2023-08-12 |
Not clear |
| Paul Kuo, Max Bellon, Judith Wishart, André J Smout, Richard H Holloway, Robert J L Fraser, Michael Horowitz, Karen L Jones, Christopher K Rayne. Effects of metoclopramide on duodenal motility and flow events, glucose absorption, and incretin hormone release in response to intraduodenal glucose infusion. American journal of physiology. Gastrointestinal and liver physiology. vol 299. issue 6. 2011-01-18. PMID:20829521. |
metoclopramide was associated with increased plasma concentrations of glp-1 (p < 0.05) and gip (p = 0.07) but lower plasma insulin concentrations (p < 0.05). |
2011-01-18 |
2023-08-12 |
human |
| Paul Kuo, Max Bellon, Judith Wishart, André J Smout, Richard H Holloway, Robert J L Fraser, Michael Horowitz, Karen L Jones, Christopher K Rayne. Effects of metoclopramide on duodenal motility and flow events, glucose absorption, and incretin hormone release in response to intraduodenal glucose infusion. American journal of physiology. Gastrointestinal and liver physiology. vol 299. issue 6. 2011-01-18. PMID:20829521. |
furthermore, glp-1 and gip release increased with metoclopramide, but insulin release paradoxically decreased. |
2011-01-18 |
2023-08-12 |
human |
| Ye-Lin Wu, Jing Huang, Jin Xu, Jian Liu, Zhen Feng, Yang Wang, Yuping Lai, Zi-Rong W. Addition of a cysteine to glucagon-like peptide-1 (GLP-1) conjugates GLP-1 to albumin in serum and prolongs GLP-1 action in vivo. Regulatory peptides. vol 164. issue 2-3. 2011-01-12. PMID:20570598. |
importantly, in glucose tolerance tests mice treated with mglp-1 exhibited much lower glucose levels and much higher insulin levels versus that in mice treated with unmodified glp-1. |
2011-01-12 |
2023-08-12 |
mouse |
| Joy Cuthbertson, Steven Patterson, Finbarr P O'Harte, Patrick M Bel. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus. Metabolism: clinical and experimental. vol 60. issue 1. 2011-01-06. PMID:20152998. |
mean auc serum insulin responses were similar after either metformin + glp-1 (5426 ± 498 mu/[l min]) or glp-1 (5655 ± 854 mu/[l min]) treatment, and both were higher than metformin (3521 ± 410 mu/[l min]; p < .001 and p < .05, respectively). |
2011-01-06 |
2023-08-12 |
human |
| Joy Cuthbertson, Steven Patterson, Finbarr P O'Harte, Patrick M Bel. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus. Metabolism: clinical and experimental. vol 60. issue 1. 2011-01-06. PMID:20152998. |
in combination with glp-1, metformin significantly lowers plasma glucose concentrations in type 2 diabetes mellitus subjects compared with glp-1 alone, whereas insulin responses were similar. |
2011-01-06 |
2023-08-12 |
human |
| Alan J Garbe. Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting. The American journal of managed care. vol 16. issue 7 Suppl. 2011-01-06. PMID:20809667. |
of the incretin-based therapies, both the dipeptidyl peptidase-4 (dpp-4) inhibitors and the glucagon-like peptide-1 (glp-1) receptor agonists stimulate insulin secretion and inhibit glucagon secretion. |
2011-01-06 |
2023-08-12 |
Not clear |
| Alethia Villasenor, Zhao V Wang, Lee B Rivera, Ozhan Ocal, Ingrid Wernstedt Asterholm, Philipp E Scherer, Rolf A Brekken, Ondine Cleaver, Thomas M Wilki. Rgs16 and Rgs8 in embryonic endocrine pancreas and mouse models of diabetes. Disease models & mechanisms. vol 3. issue 9-10. 2010-12-27. PMID:20616094. |
exendin-4, a glucagon-like peptide 1 (glp-1)/incretin mimetic that stimulates beta-cell expansion, insulin secretion and normalization of blood glucose levels in diabetics, also promoted re-expression of rgs16::gfp within a few days in pancreatic ductal-associated cells and islet beta-cells. |
2010-12-27 |
2023-08-12 |
mouse |
| Jaime A Davidso. Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors. Mayo Clinic proceedings. vol 85. issue 12 Suppl. 2010-12-20. PMID:21106865. |
in addition, unlike insulin or sulfonylureas, treatment with a glp-1 receptor agonist or a dpp-4 inhibitor has not been associated with substantial hypoglycemia. |
2010-12-20 |
2023-08-12 |
Not clear |
| Airani Sathananthan, Chiara Dalla Man, Francesco Micheletto, Alan R Zinsmeister, Michael Camilleri, Paula D Giesler, Jeanette M Laugen, Gianna Toffolo, Robert A Rizza, Claudio Cobelli, Adrian Vell. Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: a pilot study. Diabetes care. vol 33. issue 9. 2010-12-16. PMID:20805279. |
common genetic variation in glp1r and insulin secretion in response to exogenous glp-1 in nondiabetic subjects: a pilot study. |
2010-12-16 |
2023-08-12 |
human |
| Airani Sathananthan, Chiara Dalla Man, Francesco Micheletto, Alan R Zinsmeister, Michael Camilleri, Paula D Giesler, Jeanette M Laugen, Gianna Toffolo, Robert A Rizza, Claudio Cobelli, Adrian Vell. Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: a pilot study. Diabetes care. vol 33. issue 9. 2010-12-16. PMID:20805279. |
this study assessed the effect of glp1r polymorphisms on insulin secretion in response to hyperglycemia and to infused glp-1 in nondiabetic subjects. |
2010-12-16 |
2023-08-12 |
human |
| Jeremy A Lavine, Alan D Atti. Gastrointestinal hormones and the regulation of β-cell mass. Annals of the New York Academy of Sciences. vol 1212. 2010-12-14. PMID:21039588. |
glucagon-like peptide 1 (glp-1), glucose-dependent insulinotropic polypeptide (gip), cholecystokinin (cck), and gastrin are gastrointestinal hormones that are secreted in response to nutrient intake, regulating digestion, insulin secretion, satiety, and β-cell mass. |
2010-12-14 |
2023-08-12 |
Not clear |
| Mi Jin Moon, Hee Young Kim, Sin Gon Kim, Juri Park, Dong Seop Choi, Jong-Ik Hwang, Jae Young Seon. Tyr1 and Ile7 of glucose-dependent insulinotropic polypeptide (GIP) confer differential ligand selectivity toward GIP and glucagon-like peptide-1 receptors. Molecules and cells. vol 30. issue 2. 2010-12-13. PMID:20799012. |
glucagon like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip) are incretin hormones released in response to food intake and potentiate insulin secretion from pancreatic beta cells through their distinct yet related g protein-coupled receptors, glp1r and gipr. |
2010-12-13 |
2023-08-12 |
Not clear |
| A J Schee. [Saxagliptin (Onglyza): new inhibitor of the dipeptidylpeptidase-4 for the oral treatment of type 2 diabetes]. Revue medicale de Liege. vol 65. issue 9. 2010-12-10. PMID:21086586. |
it increases the circulating levels of incretin hormones (glp-1, gip), which contributes to amplify the insulin secretory response to meals and to reduce postprandial hyperglycaemia and, subsequently, fasting glycaemia. |
2010-12-10 |
2023-08-12 |
Not clear |